BUZZ-Vertex gets EU approval for next-generation cystic fibrosis drug; shares up

Reuters
02 Jul
BUZZ-Vertex gets EU approval for next-generation cystic fibrosis drug; shares up

** Shares of drugmaker Vertex Pharmaceuticals VRTX.O rise 1.6% to $452.55

** VRTX says its cystic fibrosis treatment, Alyftrek, receives European Commission approval in patients 6 years and older in EU

** Cystic fibrosis is an inherited disorder resulting from the absence of a specific protein, which disrupts the movement of salt and water in and out of cells in various organs

** The approval follows a positive recommendation in April from the European Medicines Agency, the region’s drug regulator

** The FDA approved VRTX's next-generation treatment in December and generated about $53.9 million in sales during Q1

** Including session's move, VRTX up 11.9% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10